A phase 2A, randomized, controlled, double-blind, multicenter study to evaluate the safety, tolerability, and effect on body weight of recombinant-methionyl human leptin [metreleptin; r-metHuLeptin] administered in conjunction with pramlintide in overweight and obese subjects.

Trial Profile

A phase 2A, randomized, controlled, double-blind, multicenter study to evaluate the safety, tolerability, and effect on body weight of recombinant-methionyl human leptin [metreleptin; r-metHuLeptin] administered in conjunction with pramlintide in overweight and obese subjects.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Apr 2015

At a glance

  • Drugs Metreleptin (Primary) ; Pramlintide (Primary)
  • Indications Obesity; Overweight
  • Focus Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Feb 2014 The primary endpoint and treatment arms (from 3 to 4) has been changed.
    • 01 Sep 2009 Results were published in Obesity.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top